| Budget Amount *help |
¥4,160,000 (Direct Cost: ¥3,200,000、Indirect Cost: ¥960,000)
Fiscal Year 2014: ¥2,080,000 (Direct Cost: ¥1,600,000、Indirect Cost: ¥480,000)
Fiscal Year 2013: ¥2,080,000 (Direct Cost: ¥1,600,000、Indirect Cost: ¥480,000)
|
|---|
| Outline of Final Research Achievements |
We examined the effect of Ang II on duodenal iron transporters, hepatic hepcidin, and body iron storage. Serum hepcidin-25 concentration was lower in Ang II-infused mice compared to vehicle-treated mice, and this decrease was ameliorated by angiotensin II type 1 receptor antagonist administration. Protein expression of FPN and DMT1 was increased in the duodenum of Ang II-treated mice. Iron content was elevated in kidney and peritoneal macrophage from Ang II-treated mice. These results suggest that Ang II involves in body iron metabolism through the regulation of duodenal iron transporters via hepatic hepcidin and the alteration of body iron distribution. Inhibition of Ang II has a beneficial effect on correction of abnormal iron metabolism induced by Ang II.
|
